Neurosense Therapeutics is trading at $0.43 (down 9.7%) as its multi-day decline continues despite no new company-specific news or catalysts.
- The stock has been under heavy selling pressure since July 23, falling from $0.66 to $0.47 by July 31.
- Today’s move appears to extend existing negative momentum rather than reacting to fresh fundamental developments.